Xeris Pharmaceuticals Inc (NASDAQ:XERS) has received an average rating of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $22.75.

Several equities research analysts have issued reports on XERS shares. Zacks Investment Research downgraded shares of Xeris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, September 18th. Royal Bank of Canada started coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set an “outperform” rating and a $24.00 target price on the stock. Leerink Swann started coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set an “outperform” rating and a $24.00 target price on the stock. Jefferies Financial Group started coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Mizuho started coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set a “buy” rating on the stock.

XERS stock traded up $1.59 during mid-day trading on Friday, hitting $21.00. 1,627 shares of the company were exchanged, compared to its average volume of 84,024. Xeris Pharmaceuticals has a 1-year low of $15.75 and a 1-year high of $27.98.

Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings data on Monday, August 13th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($2.19). The business had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, sell-side analysts anticipate that Xeris Pharmaceuticals will post -8.36 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in XERS. Granahan Investment Management Inc. MA bought a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $2,481,000. Redmile Group LLC bought a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $45,792,000. OppenheimerFunds Inc. bought a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $18,980,000. Citadel Advisors LLC bought a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $214,000. Finally, Dean Capital Investments Management LLC bought a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $563,000. 45.89% of the stock is currently owned by institutional investors.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Read More: Earnings Per Share

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.